Sarepta Therapeutics

SRPTNASDAQ

RNA exon-skipping and AAV gene therapy for neuromuscular disorders

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for SRPT yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

ENVISION: Delandistrogene moxeparvovec in Duchenne muscular dystrophy — primary completion

2027-05-31

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
ElevidysDuchenne muscular dystrophyApprovedNot disclosed▼
CasimersenDMD exon 45 skippingApprovedNot disclosed▼
SRP-5051Duchenne muscular dystrophyPhase 2Not disclosed▼

Analysis

We have not yet written an analysis of Sarepta Therapeutics that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade SRPT commission-free on Webullvia Webull · Affiliate

Comparable companies

Dyne TherapeuticsSolid BiosciencesRocket Pharmaceuticals

Sponsored

Get premium SRPT analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Sarepta Therapeutics has 28 Phase 2 or 3 studies on ClinicalTrials.gov: 14 completed, 8 stopped early, 6 ongoing.

14

Completed

8

Stopped early

6

Ongoing

Stopped early

  • COMPASSPhase 3 · started 2025 · withdrawn

    SRP-9005 in muscular dystrophies, limb-girdle · n=0

    Reason given: Study was Withdrawn per Sponsor decision.

  • NCT03985878Phase 2 · started 2019 · terminated

    Eteplirsen in duchenne muscular dystrophy · n=15

    Reason given: Participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment. There are no safety concerns with Eteplirsen.

  • MOMENTUMPhase 2 · started 2019 · terminated

    Vesleteplirsen in duchenne muscular dystrophy · n=62

    Reason given: The study was terminated following review of safety data.

  • NCT03675126Phase 1/2 · started 2018 · terminated

    SRP-5051 in muscular dystrophy, duchenne · n=15

    Reason given: The sponsor has decided to integrate 5051-102 into 5051-201. Participants from 5051-102 will be eligible to enroll in 5051-201 Part B.

  • NCT03652259Phase 1/2 · started 2018 · terminated

    SRP-9003 in limb-girdle muscular dystrophy, type 2e · n=6

    Reason given: Study is being terminated due to a business decision.

  • NCT03532542Phase 3 · started 2018 · terminated

    Casimersen in duchenne muscular dystrophy · n=171

    Reason given: The trial was stopped to reduce the clinical trial burden on participants while ensuring continued treatment via a post-trial access program with commercially available casimersen and golodirsen. Study was not terminated due to safety concerns.

  • NCT00451256Phase 2 · started 2007 · terminated

    AVI-5126 in cardiovascular disease · n=600

    Reason given: Protocol-defined outcome in terms of efficacy would not be achieved.

  • NCT00229749Phase 1/2 · started 2005 · terminated

    AVI-4065 Injection in hepatitis c · n=80

    Reason given: Limited viral load reduction in HCV subjects

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.